was adapted to the Portuguese setting to evaluate the cost-effectiveness (CEA) of linezolid vs.vancomycin in MRSA cSSTI. Methods: Published Bayesian evidence synthesis results were used to populate efficacy parameters of the model. Resource utilization and MRSA prevalence rates were obtained through an expert panel of Portuguese clinicians and costs from published sources were applied to resource units. Analyses were done from the Portuguese NHS perspective. Both univariate and probabilistic sensitivity analyses were performed to test the robustness of model results. Results: Average cost per patient for linezolid and vancomycin treatments were 15,195€ and 17,345€ respectively. Average effectiveness gained with linezolid treatment was 0.002QALYs. Average saving obtained with linezolid treatment was 2150€ per patient. ConClusions: Linezolid is a dominant strategy compared to vancomycin: less costly and more effective. Compared to vancomycin, linezolid is expected to result in lower total costs that offset its higher acquisition cost in cSSTI in Portugal.
PSS27 Economic Evaluation of Ranibuzumab foR thE tREatmEnt of myoPic choRoidal nEovaSculaRization in canada
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.